



# International Society for Biological Therapy of Cancer (iSBTc)

---

## ABOUT THE SOCIETY

The International Society for Biological Therapy of Cancer (iSBTc) was established in 1984 to exchange, encourage and promote information about the promise and breakthroughs of biological therapies, also called immunotherapy, for patients with cancer.

Society members include more than 500 influential leaders and scientists engaged in biological therapy of cancer, including academicians, senior researchers, clinicians, students, government representatives, and industry leaders from around the world. iSBTc's members represent 17 medical specialties and are engaged in research and treatment of at least a dozen types of cancer. The iSBTc is a 501(c)(3) non-profit group.

## MISSION

Recent advances in immunology and cancer biology have opened new horizons for cancer therapy, with increasing integration of new biologic agents into clinical practice. iSBTc's mission is to improve cancer patient outcomes by advancing the science, development, and application of biological therapy.

## GOALS

The iSBTc was founded on the belief that new systemic immunotherapeutic strategies will add to the arsenal of cancer therapies, alongside surgery, chemotherapy, radiation, and targeted therapies. To expedite the transfer of both basic and applied research to the clinical setting, iSBTc's goal is to rapidly disseminate information about biological therapy and help advance biological therapy into the mainstream of cancer therapies.

The iSBTc is dedicated to providing an open, collaborative environment for all members. In addition to hosting educational meetings and focused workshops, iSBTc undertakes initiatives centered on collaboration with other organizations both in the United States and abroad. iSBTc also works to promote discussion and disseminate information of important, emergent issues in the field. The society has developed into the premier destination for interaction and innovation in cancer biologics.